What Is Lot-to-Lot Consistency? Why It Matters for Antibody Reproducibility

Have you ever reordered an antibody only to find the new lot performs differently—weaker signal, higher background, or shifted staining pattern? Lot-to-lot variability is one of the most common sources of irreproducibility in biological research. This article explains why it happens, which antibody types are most affected, and how to protect your experiments.

Why Lot-to-Lot Variation Happens

The root cause depends on the antibody type:

Polyclonal Antibodies: High Risk

Polyclonal antibodies are produced by immunizing an animal (typically rabbit or goat) and collecting serum. Each production run (lot) involves a different bleed or even a different animal. The resulting antibody pool contains different proportions of clones with different epitope specificities and affinities. When the immunized animal is retired or dies, the original lot can never be reproduced.

Hybridoma Monoclonal Antibodies: Moderate Risk

Hybridoma-derived monoclonals come from a single clone, so the antibody sequence is fixed. However, hybridoma cell lines can undergo genetic drift over passages, leading to gradual changes in antibody glycosylation, yield, or even sequence mutations. Production conditions (media, serum, culture duration) also vary between lots.

Recombinant Monoclonal Antibodies: Lowest Risk

Recombinant antibodies are produced from a defined DNA sequence expressed in engineered host cells. Since the sequence is permanently stored and the production process is standardized, recombinant antibodies offer the highest lot-to-lot consistency available. This is why leading journals and reproducibility initiatives increasingly recommend recombinant antibodies.

How to Protect Your Experiments

• Record the lot number. Always document the catalog number AND lot number in your lab notebook and publications. This allows other researchers (and your future self) to identify exactly which antibody was used.
• Bridge-test new lots. When receiving a new lot, run it side-by-side with your remaining old lot on the same samples. Adjust working concentration if necessary.
• Stock up on good lots. When you find a lot that works well, order extra vials. For polyclonal antibodies, this is especially important.
• Switch to recombinant when possible. If consistency is critical for your project (multi-year study, clinical assay development, multi-site collaboration), recombinant monoclonal antibodies eliminate lot variation as a variable.
• Use RRIDs for reporting. Research Resource Identifiers (RRIDs) uniquely identify antibodies across suppliers and enable tracking of validated reagents in the literature.

Explore Recombinant Antibodies →